Highly active selenium nanotherapeutics combined with metformin to achieve synergistic sensitizing effect on NK cells for osteosarcoma therapy

Abstract NK cells-based cancer therapy combined with chemotherapeutic drugs for the treatment of tumors can enhance immunosensitivity cells, increase expression cell receptors, and eventually boost killing effect cells on cells. Selenium (Se) different chemical structures be metabolized into selenoproteins to regulate tumor immune cells’ fate functions. Herein, we found that, functionalized Se nanoparticles (SeNPs) combining metformin (met) could amply immunotherapeutic effects NK92 against osteosarcoma cancer. The results revealed that TW80-SeNPs met had optimum performance HepG2 owing increased ROS in augmented surface receptor proteins ULBP-3/4, PD-L1, MICA, PD-1 FasL. Additionally, were gradually (Gpx4 TR1) human MG63 reinforce anticancer by regulating redox balance microenvironment. This study provides a therapeutic approach treating itself or diabetes coupled Moreover, it multidrug strategy improve function practical applications, especially synergistic immunotherapy osteosarcoma.